The investigators performed the assessment in 334 type 2 diabetic patients seen over 3 years. They evaluated initial and latest values of HbA1c, systolic and diastolic blood pressure, body mass index, low-density lipoprotein, high-density lipoprotein, triglycerides, and the use of various antidiabetic, antihypertensive, and lipid-lowering agents.

In the Endocrine and Diabetes Center, 28.7% of their patients reached all NHANES IV target goals in their most recent office visits. With application of ADA guidelines, however, 9.3% of patients reached five, 27.8% four, 27.8% three, 21.6% two, 10.2% one, and 3.3% none of the target goals.

Monotherapy antidiabetic agents were used in 24.9% of these patients; a two-drug regimen was used in 41.3%, a three-drug regimen in 22.5%, a three-drug regimen plus insulin in 6%; and lifestyle modification in 5.3%.

Regarding antihypertensive medications, 41.6% were taking one, 22.8% two, 8.4% three, and 3% more than three drugs; 24.2% of patients were not taking any antihypertensive drug.

In the lipid-lowering category, 62.9% were receiving monotherapy, 9% two drugs, and 28.1% no lipid-lowering therapy.